Cabaletta Bio (CABA) Akcie Kurz
Cabaletta Bio Kurz
Cena akcie Cabaletta Bio
Tato data přes Eulerpool API
100 000 požadavků/měs. zdarma · bez karty
Obchodní model Cabaletta Bio a analýza akcií
Nejčastější otázky týkající se akcie Cabaletta Bio
The business model of Cabaletta Bio Inc focuses on the development and commercialization of cell therapy products for the treatment of B cell-mediated autoimmune diseases. As a clinical-stage biotechnology company, Cabaletta Bio Inc aims to utilize its proprietary technology platform, the proprietary Chimeric AutoAntibody Receptor (CAAR) T-cell technology, to engineer T cells that can selectively eliminate autoreactive B cells. By targeting the underlying cause of autoimmune diseases, Cabaletta Bio Inc strives to provide potentially curative therapies for patients suffering from diseases such as mucosal pemphigus vulgaris and mucosal pemphigoid.
Cabaletta Bio Inc is primarily active in the biotechnology industry.
The main competitors of Cabaletta Bio Inc in the market include companies such as Passage Bio, Audentes Therapeutics, and Axovant Gene Therapies. These companies are also involved in the development and commercialization of novel gene therapies aimed at treating various diseases.
Cabaletta Bio Inc. is a biopharmaceutical company that focuses on the development of engineered T-cell therapies for patients with B cell-mediated autoimmune diseases. The company was founded in 2017, with its headquarters in Radnor, Pennsylvania, United States. Cabaletta Bio Inc. aims to harness the power of its proprietary CAR-T cell platform to create transformative therapies that selectively eliminate only the cells responsible for autoimmune diseases, while sparing healthy cells. With a strong emphasis on research and product development, Cabaletta Bio Inc. is dedicated to advancing innovative treatment options for patients suffering from severe autoimmune disorders.
Cabaletta Bio Inc has achieved several significant milestones. The company successfully completed its initial public offering (IPO) in 2018, raising capital to support its innovative cell therapy programs. Additionally, Cabaletta Bio has entered into strategic partnerships, including a collaboration with Medison Pharma, to accelerate the development and commercialization of potential therapies. Moreover, the company has made progress in advancing its lead product candidate, DSG3-CAART, through clinical trials. Cabaletta Bio Inc's dedication to advancing precision engineered cell therapies has positioned it as a promising player in the field of immune-mediated diseases.
Cabaletta Bio Inc is primarily present in the United States.
Cabaletta Bio Inc represents a strong commitment to developing transformative therapies for patients with B cell-mediated autoimmune diseases. The company's core values focus on innovation, scientific excellence, and dedication to improving patient lives. Cabaletta Bio Inc adopts a patient-centric approach, aiming to deliver novel, scalable, and curative Chimeric AutoAntibody Receptor (CAAR) T-cell therapies. The company's corporate philosophy revolves around collaboration, conducting robust research, and harnessing cutting-edge technologies to address unmet medical needs. Cabaletta Bio Inc strives to achieve clinical advancements, build strategic partnerships, and contribute to the overall advancement of precision medicine in the field of autoimmune diseases.
16 analytiků aktuálně hodnotí akcii Cabaletta Bio: 13 doporučuje koupit, 3 držet a 0 prodat. Pro rok 2026 analytici očekávají u Cabaletta Bio tržby 2,50 Mil. USD a zisk na akcii -1,28 USD.
Při aktuálním kurzu se akcie Cabaletta Bio obchoduje za 1,42 EUR (1,60 USD).
Akcie Cabaletta Bio (CABA) je kótována na 1 burzách, mimo jiné: NASDAQ (CABA).
The company Cabaletta Bio Inc is a biopharmaceutical company that develops personalized therapies for patients with rare hereditary autoimmune diseases. Cabaletta Bio's business model is based on the use of CAR-T cell therapies tailored to the individual needs of each patient. Cabaletta Bio Inc debuted on the Nasdaq stock exchange in 2018 to finance the company's further growth. Through the Initial Public Offering (IPO), Cabaletta Bio raised $74 million and valued the company at approximately $390 million. Cabaletta Bio's research focuses on three main areas. Firstly, the identification of rare hereditary autoimmune diseases and the development of personalized CAR-T cell therapies. Secondly, the discovery of innovative technologies for CAR-T cell manufacturing. And thirdly, collaboration with leading researchers, universities, and hospitals to improve CAR-T cell therapies. Currently, Cabaletta Bio's key products are the AUTO1 CAR-T cell therapies developed for the treatment of patients with cutaneous T-cell lymphopenia (CTCL) and mucous membrane pemphigoid (MMP). AUTO1 is a personalized therapy manufactured from the patient's own T-cells. The CAR-T cells are designed to specifically target the disease-causing cells of the patient. Cabaletta Bio has also developed a platform technology that enhances the effectiveness of CAR-T cell therapy. This platform, called HeLaMo, is based on the use of helper T-cells to amplify the activity of CAR-T cells in the patient's body. HeLaMo also improves the safety and efficiency of treatment. Cabaletta Bio also has an extensive pipeline of therapies in development targeting various autoimmune diseases. These include autoimmune diseases of the skin, eyes, and central nervous system. Cabaletta Bio's business model is based on partnerships with leading institutions and regulatory agencies. The company has partnerships with the National Institute of Allergy and Infectious Diseases (NIAID) and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Cabaletta Bio has also formed a strategic partnership with Regeneron Pharmaceuticals to harness the potential of Cabaletta Bio's technology platform in the field of autoimmune diseases of the eye. Cabaletta Bio is a rapidly growing company with a promising portfolio of personalized CAR-T cell therapies. The company is committed to improving the lives of patients with rare autoimmune diseases and revolutionizing the treatment of autoimmune diseases.
Tržby očekávané za Cabaletta Bio činí 2,50 Mil. USD. Tato hodnota je založena na aktuálních finančních údajích a odráží výkonnost společnosti.
Zisk očekávané za Cabaletta Bio činí -131,11 Mil. USD. Čistý zisk odráží ziskovost společnosti po odečtení všech nákladů.
Poměr ceny k zisku (P/E) Cabaletta Bio je aktuálně -1,24. Poměr P/E porovnává aktuální cenu akcie se ziskem na akcii a pomáhá investorům posoudit ocenění akcie Cabaletta Bio.
Poměr ceny k tržbám (P/S) Cabaletta Bio je aktuálně 65,24. Poměr P/S porovnává tržní kapitalizaci s ročními tržbami a slouží jako metrika ocenění akcie Cabaletta Bio.
Score kvality pro Cabaletta Bio je 2/10.
ISIN Cabaletta Bio je US12674W1099. ISIN (International Securities Identification Number) je celosvětově jedinečný identifikátor cenných papírů.
WKN Cabaletta Bio je A2PTTB. WKN (Wertpapierkennnummer) je šestimístný německý identifikační kód cenného papíru.
Ticker Cabaletta Bio je CABA. Symbol tickeru se používá k obchodování akcií Cabaletta Bio na burze.
Cabaletta Bio akcie
Cabaletta Bio Peer Group
Cabaletta Bio Ticker
Cabaletta Bio FIGI
Všechny fundamentální údaje o Cabaletta Bio v podrobné analýze
Naše analýzy akcií společnosti Cabaletta Bio zahrnují důležité finanční ukazatele jako obrat, zisk, P/E poměr, P/S poměr, EBIT, stejně jako informace o dividendách. Dále zkoumáme aspekty jako akcie, tržní kapitalizaci, dluhy, vlastní kapitál a závazky společnosti Cabaletta Bio. Pokud hledáte podrobnější informace o těchto tématech, nabízíme vám na našich podstránkách rozsáhlé analýzy: